Ocugen, INC 10-Q quarterly reports

Ocugen, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing clinical development and significant net losses, leading to substantial doubt about its ability to continue as a going concern.

Ocugen reported increased net losses and a going concern warning, despite pipeline progress and a new licensing deal, as a merger agreement terminated.

Ocugen, Inc. reported increased net losses for Q2 2025, citing substantial doubt about its going concern ability, while advancing multiple gene therapy programs and announcing a NeoCart business merger.

Ocugen's Q1 2025 results show increased revenue but a larger net loss, with ongoing clinical trial advancements overshadowed by concerns about the company's ability to continue as a going concern.

Ocugen's Q3 2024 report reveals a net loss of $12.97 million, alongside progress in clinical trials and a recent debt financing transaction.

Ocugen's Q2 2024 report highlights progress in its gene therapy programs, including the initiation of a Phase 3 trial for OCU400, while also addressing financial challenges and a material weakness in internal controls.

Ocugen's Q1 2024 report shows a net loss of $11.9 million, progress in clinical trials, and ongoing efforts to secure additional funding.